BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Beig J, Orr D, Harrison B, Gane E. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients. Liver Transpl 2018;24:1031-9. [PMID: 29577581 DOI: 10.1002/lt.25060] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Srivastava P, Agrawal A, Jha A. Postoperative Renal Dysfunction in Recipient. Peri-operative Anesthetic Management in Liver Transplantation 2023. [DOI: 10.1007/978-981-19-6045-1_40] [Reference Citation Analysis]
2 Rusman RD, Daud NA, Parewangi ML, Bakri S, Aman AM, Rasyid H, Seweng A, Tahir AS. Correlation of host factor with virological response to direct-acting antiviral treatment in hepatitis C patients. Egypt Liver Journal 2022;12:52. [DOI: 10.1186/s43066-022-00217-9] [Reference Citation Analysis]
3 Rusman RD, Daud NA, Parewangi ML, Bakri S, Aman AM, Rasyid H, Seweng A, Tahir AS. Correlation of host factor with virological response to direct-acting antiviral treatment in hepatitis C patients. Egypt Liver Journal 2022;12:52. [DOI: 10.1186/s43066-022-00217-9] [Reference Citation Analysis]
4 Liu H, Yang XL, Dong ZR, Chen ZQ, Hong JG, Wang DX, Li T. Clinical benefits of direct-acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta-analysis. J Gastroenterol Hepatol 2022;37:1654-65. [PMID: 35722709 DOI: 10.1111/jgh.15915] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Casas-deza D, Martínez-sapiña A, Espina S, Garcia-rodriguez B, Fernandez-bonilla EM, Sanz-paris A, Gonzalez-irazabal Y, Bernal-monterde V, Arbones-mainar JM. Evaluation of Cardiovascular Risk Factors after Hepatitis C Virus Eradication with Direct-Acting Antivirals in a Cohort of Treatment-Naïve Patients without History of Cardiovascular Disease. JCM 2022;11:4049. [DOI: 10.3390/jcm11144049] [Reference Citation Analysis]
6 Wang YK, Wang YW, Lu CL, Huang YH, Hou MC, Chang YL, Lee WP, Lan KH. Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol. Sci Rep 2022;12:9942. [PMID: 35705594 DOI: 10.1038/s41598-022-13657-5] [Reference Citation Analysis]
7 Hagag RY, Selim AF, Darrag OM, Zied H, Aboelnasr MS. Does Hepatitis C Virus Treatment by Directly Acting Antivirals Obligate Shifting Patients with Type 2 Diabetes from Oral Hypoglycemic Drugs to Insulin Therapy? Diabetes Metab Syndr Obes 2022;15:1261-8. [PMID: 35502409 DOI: 10.2147/DMSO.S354023] [Reference Citation Analysis]
8 Sirpal S, Chandok N. Barriers to hepatitis C diagnosis and treatment in the DAA era: Preliminary results of a community-based survey of primary care practitioners. CanLivJ 2022;5:96-100. [DOI: 10.3138/canlivj-2021-0032] [Reference Citation Analysis]
9 Lee H, Chien RN, Pao LH, Kuo CJ, Huang PH, Chang ML. Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study. Cells 2021;10:2934. [PMID: 34831156 DOI: 10.3390/cells10112934] [Reference Citation Analysis]
10 Wang YW, Lee WP, Huang YH, Hou MC, Lan KH. Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis. BMC Infect Dis 2021;21:984. [PMID: 34548026 DOI: 10.1186/s12879-021-06657-9] [Reference Citation Analysis]
11 Sagnelli E, Sagnelli C, Russo A, Pisaturo M, Camaioni C, Astorri R, Coppola N. Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review. Adv Exp Med Biol 2021;1323:115-47. [PMID: 33326112 DOI: 10.1007/5584_2020_604] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Su X, Zhao X, Deng JL, Li SN, Du X, Dong JZ, Ma CS. Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta-analysis. J Viral Hepat 2021;28:664-71. [PMID: 33452699 DOI: 10.1111/jvh.13469] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
13 Ciancio A, Ribaldone DG, Dotta A, Giordanino C, Sacco M, Fagoonee S, Pellicano R, Saracco GM. Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C successfully treated with direct-acting antiviral agents. Liver Int 2021;41:276-87. [PMID: 32998174 DOI: 10.1111/liv.14676] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
14 Villani R, Romano AD, Sangineto M, Serviddio G. Direct-acting antivirals improve kidney function in diabetic patients with HCV infection and chronic kidney disease. Intern Emerg Med 2021;16:1239-45. [PMID: 33471254 DOI: 10.1007/s11739-020-02628-1] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Butt AA, Yan P, Aslam S, Shaikh OS, Abou-Samra AB. Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES). Clin Infect Dis 2020;70:1153-60. [PMID: 30977808 DOI: 10.1093/cid/ciz304] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
16 Iossa D, Vitrone M, Gagliardi M, Falco E, Ragone E, Zampino R, Durante-Mangoni E. Anthropometric parameters and liver histology influence lipid metabolic changes in HCV chronic hepatitis on direct-acting antiviral treatment. Ann Transl Med 2021;9:35. [PMID: 33553328 DOI: 10.21037/atm-20-669] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Cázares-Cortazar A, Uribe-Noguez LA, Mata-Marín JA, Gaytán-Martínez J, de la Luz Martínez-Rodríguez M, Villavicencio-Ferrel PE, Chapararro-Sánchez A, Mauss S, Ocaña-Mondragón A. A decrease in hepatitis C virus RNA to undetectable levels in chronic hepatitis C patients after PegIFNα + RVB or sofosbuvir + NS5A inhibitor treatment is associated with decreased insulin resistance and persistent oxidative stress. Arch Virol 2020;165:2759-66. [PMID: 32885325 DOI: 10.1007/s00705-020-04797-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Mohanty A, Salameh S, Butt AA. Impact of Direct Acting Antiviral Agent Therapy upon Extrahepatic Manifestations of Hepatitis C Virus Infection. Curr HIV/AIDS Rep 2019;16:389-94. [PMID: 31482299 DOI: 10.1007/s11904-019-00466-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
19 Hsu CS, Liu WL, Li Q, Lowey B, Hertz L, Chao YC, Liang TJ, Chen DS, Kao JH. Hepatitis C virus genotypes 1-3 infections regulate lipogenic signaling and suppress cholesterol biosynthesis in hepatocytes. J Formos Med Assoc 2020;119:1382-95. [PMID: 32284164 DOI: 10.1016/j.jfma.2020.03.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Ribaldone DG, Sacco M, Saracco GM. The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm. J Clin Med. 2020;9. [PMID: 32092892 DOI: 10.3390/jcm9020563] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
21 Collins LF, Adekunle RO, Cartwright EJ. Metabolic Syndrome in HIV/HCV Co-infected Patients. Curr Treat Options Infect Dis 2019;11:351-71. [PMID: 32030090 DOI: 10.1007/s40506-019-00207-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Neugarten J, Golestaneh L. Liver Disease and Chronic Kidney Disease. Chronic Renal Disease 2020. [DOI: 10.1016/b978-0-12-815876-0.00053-x] [Reference Citation Analysis]
23 Purdy JG, Luftig MA. Reprogramming of cellular metabolic pathways by human oncogenic viruses. Curr Opin Virol 2019;39:60-9. [PMID: 31766001 DOI: 10.1016/j.coviro.2019.11.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
24 Villani R, Monami M, Di Cosimo F, Fioravanti G, Mannucci E, Vendemiale G, Serviddio G. Direct-acting antivirals for HCV treatment in older patients: A systematic review and meta-analysis. J Viral Hepat 2019;26:1249-56. [PMID: 31243849 DOI: 10.1111/jvh.13169] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
25 Morihara D, Ko YL, Shibata K, Yamauchi R, Fukuda H, Tsuchiya N, Fukunaga A, Kunimoto H, Iwashita H, Takata K, Tanaka T, Sakurai K, Inomata S, Yokoyama K, Nishizawa S, Takeyama Y, Irie M, Shakado S, Sohda T, Sakisaka S. IL28B gene polymorphism is correlated with changes in low-density lipoprotein cholesterol levels after clearance of hepatitis C virus using direct-acting antiviral treatment. J Gastroenterol Hepatol 2019;34:2019-27. [PMID: 31144350 DOI: 10.1111/jgh.14741] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
26 Carnovale C, Pozzi M, Dassano A, D'Addio F, Gentili M, Magni C, Clementi E, Radice S, Fiorina P. The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis. Acta Diabetol 2019;56:341-54. [PMID: 30478781 DOI: 10.1007/s00592-018-1257-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
27 Lim TR, Hazlehurst JM, Oprescu AI, Armstrong MJ, Abdullah SF, Davies NP, Flintham R, Balfe P, Mutimer DJ, McKeating JA, Tomlinson JW. Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure. Clin Endocrinol (Oxf). 2019;90:440-448. [PMID: 30586166 DOI: 10.1111/cen.13924] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
28 Lanini S, Scognamiglio P, Pisapia R, Minosse C, Agresta A, Ippolito G. Recovery of metabolic impairment in patients who cleared chronic hepatitis C infection after direct-acting antiviral therapy. Int J Antimicrob Agents 2019;53:559-63. [PMID: 30550818 DOI: 10.1016/j.ijantimicag.2018.11.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
29 Drazilova S, Janicko M, Skladany L, Kristian P, Oltman M, Szantova M, Krkoska D, Mazuchova E, Piesecka L, Vahalova V, Rac M, Schreter I, Virag L, Koller T, Liptakova A, Ondrasova M, Jarcuska P. Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals. Can J Gastroenterol Hepatol 2018;2018:6095097. [PMID: 30402450 DOI: 10.1155/2018/6095097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
30 Drazilova S, Gazda J, Janicko M, Jarcuska P. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Can J Gastroenterol Hepatol 2018;2018:6150861. [PMID: 30186821 DOI: 10.1155/2018/6150861] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
31 Agarwal K, Brown SE. Achieving Cure From Hepatitis C Virus Is Good for More Than Just the Liver Graft. Liver Transpl 2018;24:997-8. [PMID: 30028069 DOI: 10.1002/lt.25298] [Reference Citation Analysis]